| Literature DB >> 32669285 |
Chris Bailey1, James R M Black2, Charles Swanton3,4,5.
Abstract
The COVID-19 pandemic has caused widespread disruption of cancer clinical trials due to the restrictions on nonessential services and the reallocation of resources, and at the same time the urgent global effort toward discovering therapies that treat or prevent COVID-19 infection has led to shortening of traditional regulatory timelines. This experience should stimulate similar urgency in the way future cancer research is conducted. ©2020 American Association for Cancer Research.Entities:
Mesh:
Year: 2020 PMID: 32669285 DOI: 10.1158/2159-8290.CD-20-0823
Source DB: PubMed Journal: Cancer Discov ISSN: 2159-8274 Impact factor: 38.272